LIVE WEBINAR

Impact of Obesity Pharmacotherapies on Behavioral Health

OVERVIEW

Pharmacotherapy is an important tool in obesity management. Understanding its effects on behavioral health is essential. This webinar will examine the relationship between obesity medications and mental health outcomes.

LEARNING OBJECTIVES

Identify the major classes of pharmacotherapies used in obesity management and their potential effects on behavioral health.
Recognize the mechanisms by which obesity medications may influence mental health outcomes, including both benefits and risks.
Evaluate patient case scenarios to determine appropriate obesity pharmacotherapy options, considering behavioral health factors and evidence-based guidelines.

DATE & TIME

Mar 18, 2026 4:00 PM - 5:15 PM ET

FACULTY

Dr. Janelle Coughlin, PhD
Associate Director, Center for Behavior and Health
Director, Obesity Behavioral Medicine Program Johns Hopkins

FACULTY

Jessica Bartfield, MD
Clinical Associate Professor at Wake Forest University School of Medicine

Novo Nordisk is a strategic supporter of the Obesity Association, a division of the American Diabetes Association.

Note: You do not need to be an ADA professional member to access our free continuing education programs. Simply create a free account and start exploring 70+ free CE courses. Login to get started!